LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that all purchasers of the securities of Orthofix International N.V. (“Orthofix” or the “Company”) (NASDAQ:OFIX) between May 5, 2011 and July 29, 2013, inclusive (the “Class Period’), have until October 14, 2013 to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Southern District of New York.

“Class Period’), have until October 14, 2013 to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Southern District of New York.”

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888) 773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.

Orthofix is a medical device company engaged in the design, development, manufacturing, marketing and distribution of medical equipment for spine and orthopedic applications. The Complaint alleges that defendants misrepresented or failed to disclose that: (1) certain revenues recognized during 2011 and 2012 should not have been recognized or were recognized improperly; (2) Orthofix’s previously issued consolidated financial statements as of and for the fiscal years ended December 31, 2011 and December 31, 2012, the interim quarterly periods within those years, and for the interim quarterly period ended March 31, 2013 should not be relied upon; (3) Orthofix’s financial statements during 2011, 2012 and the first quarter of 2013 were materially false and misleading and violated generally accepted accounting principles and the Company’s revenue recognition policy; (4) Orthofix’s Forms 10-Q and 10-K for fiscal years 2011, 2012, and the first quarter of 2013, failed to disclose then-known trends, events or uncertainties associated with the Company’s revenues that were reasonably likely to have a material effect on Orthofix’s future operating results; (5) the Company’s disclosure controls and procedures over financial reporting were materially deficient, and defendants’ representations during the Class Period concerning those controls and procedures were materially false and misleading; and (6) as a result of the foregoing, defendants lacked a reasonable basis for their positive statements about the Company’s financial performance and outlook during the Class Period.

If you are a member of the Class described above you may move the Court no later than October 14, 2013 to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.

To learn more about this action or if you have any questions concerning this Notice or your rights or interests with respect to these matters, or if you purchased Orthofix shares prior to the Class Period, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.